PreAnalytiX Launches First Product

PAXgene Blood RNA System Designed for RNA Stabilization and

Greater Accuracy in Gene Expression Analysis



Apr 18, 2001, 01:00 ET from PreAnalytiX GmbH

    HOMBRECHTIKON, Switzerland, April 18 /PRNewswire Interactive News Release/
 -- PreAnalytiX GmbH, an equally owned joint venture between QIAGEN N.V.
 (Nasdaq:   QGENF, Frankfurt Neuer Markt: QIA, Easdaq: QGEN) and BD (Becton,
 Dickinson and Company) (NYSE:   BDX) announced today the launch of its first
 product, the PAXgene(TM) Blood RNA System.  By consolidating and integrating
 the key steps of sample collection, stabilization and purification, the
 PAXgene Blood RNA System is designed to minimize the chronic problems
 associated with preanalytical process variability and to eliminate much of the
 unpredictability that has been a critical limitation in RNA analysis.
     Due to the significant information content of RNA, this molecule is widely
 analyzed in clinical research, molecular diagnostics and genomics.  Unlike
 DNA, RNA is highly unstable. Studies have demonstrated that many messenger RNA
 species are being up-and down regulated or degraded in vitro after blood
 collection and during sample transportation and processing. PreAnalytiX has
 demonstrated that immediate stabilization of RNA is not only advantageous, but
 is also a critical requirement for detection of certain RNA patterns. Data
 from on-going studies shows that the PAXgene Blood RNA System produces
 superior quality and quantity of gene expression information when using
 RT-PCR, real time RT-PCR or microarrays.
     The PAXgene Blood RNA System combines BD's leadership in the area of
 sample collection for clinical laboratories with QIAGEN's leadership in the
 area of stabilization and purification of nucleic acids.  A first of its kind,
 it employs an evacuated blood collection device with a proprietary PreAnalytiX
 reagent that, in a single blood draw, rapidly protects and stabilizes RNA.
 The system eliminates the need for expensive and immediate freezing, allowing
 transport and storage at room temperature for periods well exceeding what is
 required in sample logistics.  The system's purification kit uses proven
 separation and purification technologies from QIAGEN and process chemistry
 designed to optimize the quality and quantity of RNA from samples stabilized
 in the PreAnalytiX reagent.
     Dr. Helge Bastian, Vice President of PreAnalytiX and QIAGEN's Molecular
 Diagnostic Division, stated: "An accurate picture of in vivo gene expression
 is essential for understanding gene regulation as it relates to different
 disease states and a patient's response to drug therapy.  Our novel PAXgene
 Blood RNA System adds a completely new dimension to gene expression analysis
 by enabling researchers and clinicians to find the subtle differences in gene
 expression profiles without the variations caused by sample collection,
 storage and transport conditions.  This may make the resultant analytical
 information of greater clinical relevance in that it reflects what is truly
 occurring in the patient.  We believe the technology in the PAXgene Blood RNA
 System allows one to discover differences in gene expression that would have
 been overlooked or misinterpreted using traditional methods."
     "We are pleased to have our first product come to market within 18 months
 after forming PreAnalytiX", said Frank Augello, Vice President of PreAnalytiX
 and Business Director, BD Preanalytical Solutions.  "We have integrated
 technologies from BD and QIAGEN to develop a product that will enhance the
 accuracy of intracellular RNA analysis from whole blood.  We believe the
 PAXgene Blood RNA System is a genuine enabling technology that will allow
 users to take an 'in vivo snapshot' of a person's gene expression pattern."
     PreAnalytiX believes that the PAXgene Blood RNA System will have an
 important impact in clinical research, molecular diagnostics and genomics,
 especially in high-volume clinical trials where complex sample logistics,
 multiple sites and long transport times are issues.  As predictive,
 prognostic, and diagnostic applications for gene expression analysis continue
 to rapidly evolve, PreAnalytiX believes that the PAXgene Blood RNA System will
 enable faster, more accurate, and higher quality nucleic acid test results.
 PreAnalytiX is pioneering integrated systems to standardize the collection,
 stabilization, isolation and purification of RNA and DNA from a range of
 samples, including whole blood, bone marrow, and a multitude of tissues.
 
     Certain of the statements contained in this news release may be considered
 forward-looking statements within the meaning of Section 27A of the U.S.
 Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
 Exchange Act of 1934, as amended.  To the extent that any of the statements
 contained herein relating to QIAGEN's, BD's or PreAnalytiX' products and
 markets and operating results are forward-looking, such statements are based
 on current expectations of their respective managements, which expectations
 involve a number of uncertainties and risks.  Such uncertainties and risks
 include, but are not limited to, risks associated with the challenges of
 integrating newly-acquired businesses and technologies into existing
 operations, management of growth and international operations (including the
 effects of currency fluctuations), variability of operating results, the
 commercial development of the DNA sequencing and genomics market, and the
 nucleic acid  based molecular diagnostics market, competition, rapid or
 unexpected changes in technologies, product development risks, the ability to
 gain market acceptance of such products and fluctuations in demand for such
 products (including seasonal fluctuations), difficulties in successfully
 adapting such products to integrated solutions and producing such products,
 the ability to identify and develop new products and to differentiate such
 products from competitors, and uncertainties of government regulation.  For
 further information with respect to QIAGEN, refer to the discussion in reports
 that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
 Reference is also made to the other risks and uncertainties detailed from time
 to time in BD's filings with the SEC. QIAGEN, BD and PreAnalytiX do not intend
 to update any forward-looking statements.
 
     CONTACTS:
 
     Dr. Helge Bastian
     Vice President
     PreAnalytiX GmbH
     h.bastian@de.qiagen.com
     +49 (2103) 29-16260
 
     Dr. Solveigh Mahler
     Head of Investor Relations
     QIAGEN N.V.
     s.maehler@de.qiagen.com
     +49 (2103) 29-11710
 
     BD:
     Dean Paranicas / Investor Relations
     +1 (201) 847-7102
     Camilla Jenkins / Media Relations
     +1 (201) 847-5369
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X90757446
 
 

SOURCE PreAnalytiX GmbH
    HOMBRECHTIKON, Switzerland, April 18 /PRNewswire Interactive News Release/
 -- PreAnalytiX GmbH, an equally owned joint venture between QIAGEN N.V.
 (Nasdaq:   QGENF, Frankfurt Neuer Markt: QIA, Easdaq: QGEN) and BD (Becton,
 Dickinson and Company) (NYSE:   BDX) announced today the launch of its first
 product, the PAXgene(TM) Blood RNA System.  By consolidating and integrating
 the key steps of sample collection, stabilization and purification, the
 PAXgene Blood RNA System is designed to minimize the chronic problems
 associated with preanalytical process variability and to eliminate much of the
 unpredictability that has been a critical limitation in RNA analysis.
     Due to the significant information content of RNA, this molecule is widely
 analyzed in clinical research, molecular diagnostics and genomics.  Unlike
 DNA, RNA is highly unstable. Studies have demonstrated that many messenger RNA
 species are being up-and down regulated or degraded in vitro after blood
 collection and during sample transportation and processing. PreAnalytiX has
 demonstrated that immediate stabilization of RNA is not only advantageous, but
 is also a critical requirement for detection of certain RNA patterns. Data
 from on-going studies shows that the PAXgene Blood RNA System produces
 superior quality and quantity of gene expression information when using
 RT-PCR, real time RT-PCR or microarrays.
     The PAXgene Blood RNA System combines BD's leadership in the area of
 sample collection for clinical laboratories with QIAGEN's leadership in the
 area of stabilization and purification of nucleic acids.  A first of its kind,
 it employs an evacuated blood collection device with a proprietary PreAnalytiX
 reagent that, in a single blood draw, rapidly protects and stabilizes RNA.
 The system eliminates the need for expensive and immediate freezing, allowing
 transport and storage at room temperature for periods well exceeding what is
 required in sample logistics.  The system's purification kit uses proven
 separation and purification technologies from QIAGEN and process chemistry
 designed to optimize the quality and quantity of RNA from samples stabilized
 in the PreAnalytiX reagent.
     Dr. Helge Bastian, Vice President of PreAnalytiX and QIAGEN's Molecular
 Diagnostic Division, stated: "An accurate picture of in vivo gene expression
 is essential for understanding gene regulation as it relates to different
 disease states and a patient's response to drug therapy.  Our novel PAXgene
 Blood RNA System adds a completely new dimension to gene expression analysis
 by enabling researchers and clinicians to find the subtle differences in gene
 expression profiles without the variations caused by sample collection,
 storage and transport conditions.  This may make the resultant analytical
 information of greater clinical relevance in that it reflects what is truly
 occurring in the patient.  We believe the technology in the PAXgene Blood RNA
 System allows one to discover differences in gene expression that would have
 been overlooked or misinterpreted using traditional methods."
     "We are pleased to have our first product come to market within 18 months
 after forming PreAnalytiX", said Frank Augello, Vice President of PreAnalytiX
 and Business Director, BD Preanalytical Solutions.  "We have integrated
 technologies from BD and QIAGEN to develop a product that will enhance the
 accuracy of intracellular RNA analysis from whole blood.  We believe the
 PAXgene Blood RNA System is a genuine enabling technology that will allow
 users to take an 'in vivo snapshot' of a person's gene expression pattern."
     PreAnalytiX believes that the PAXgene Blood RNA System will have an
 important impact in clinical research, molecular diagnostics and genomics,
 especially in high-volume clinical trials where complex sample logistics,
 multiple sites and long transport times are issues.  As predictive,
 prognostic, and diagnostic applications for gene expression analysis continue
 to rapidly evolve, PreAnalytiX believes that the PAXgene Blood RNA System will
 enable faster, more accurate, and higher quality nucleic acid test results.
 PreAnalytiX is pioneering integrated systems to standardize the collection,
 stabilization, isolation and purification of RNA and DNA from a range of
 samples, including whole blood, bone marrow, and a multitude of tissues.
 
     Certain of the statements contained in this news release may be considered
 forward-looking statements within the meaning of Section 27A of the U.S.
 Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
 Exchange Act of 1934, as amended.  To the extent that any of the statements
 contained herein relating to QIAGEN's, BD's or PreAnalytiX' products and
 markets and operating results are forward-looking, such statements are based
 on current expectations of their respective managements, which expectations
 involve a number of uncertainties and risks.  Such uncertainties and risks
 include, but are not limited to, risks associated with the challenges of
 integrating newly-acquired businesses and technologies into existing
 operations, management of growth and international operations (including the
 effects of currency fluctuations), variability of operating results, the
 commercial development of the DNA sequencing and genomics market, and the
 nucleic acid  based molecular diagnostics market, competition, rapid or
 unexpected changes in technologies, product development risks, the ability to
 gain market acceptance of such products and fluctuations in demand for such
 products (including seasonal fluctuations), difficulties in successfully
 adapting such products to integrated solutions and producing such products,
 the ability to identify and develop new products and to differentiate such
 products from competitors, and uncertainties of government regulation.  For
 further information with respect to QIAGEN, refer to the discussion in reports
 that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
 Reference is also made to the other risks and uncertainties detailed from time
 to time in BD's filings with the SEC. QIAGEN, BD and PreAnalytiX do not intend
 to update any forward-looking statements.
 
     CONTACTS:
 
     Dr. Helge Bastian
     Vice President
     PreAnalytiX GmbH
     h.bastian@de.qiagen.com
     +49 (2103) 29-16260
 
     Dr. Solveigh Mahler
     Head of Investor Relations
     QIAGEN N.V.
     s.maehler@de.qiagen.com
     +49 (2103) 29-11710
 
     BD:
     Dean Paranicas / Investor Relations
     +1 (201) 847-7102
     Camilla Jenkins / Media Relations
     +1 (201) 847-5369
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X90757446
 
 SOURCE  PreAnalytiX GmbH